nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

17.09.2018 | Review Article

Autophagy therapeutics: preclinical basis and initial clinical studies

verfasst von: Lei Zhan, Jun Li, Bing Wei

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Autophagy captures and degrades intracellular components such as proteins and organelles to sustain metabolism and homeostasis. Rapidly accumulating attention is being paid to the role of autophagy in the development of cancer, which makes autophagy attractive tools and targets for novel therapeutic approaches. Functional studies have confirmed that autophagy dysregulation is causal in many cases of cancer, with autophagy acting as tumor suppressors or tumor promoters, and autophagy inhibitor or promoter has shown promise in preclinical studies. The autophagy-targeted therapeutics using chloroquine/hydroxychloroquine have reached clinical development for treating cancer, but these drugs are actually not efficient probably because of a reduced penetration within the tumor. In this review, we first discuss the discoveries related to dual function of autophagy in cancer. Then, we provide an overview of preclinical studies and clinical trials involved in the development of autophagy therapeutics and finally discuss the future of such therapies.

De Duve C, Wattiaux R (1966) Functions of lysosomes. Annu Rev Physiol 28:435–492. https://doi.org/10.1146/annurev.ph.28.030166.002251 CrossRefPubMed

Tsukada M, Ohsumi Y (1993) Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett 333(1–2):169–174. https://doi.org/10.1016/0014-5793(93)80398-E CrossRefPubMed

Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, Follenzi A, Potolicchio I, Nieves E, Cuervo AM, Santambrogio L (2011) Microautophagy of cytosolic proteins by late endosomes. Dev Cell 20(1):131–139. https://doi.org/10.1016/j.devcel.2010.12.003 CrossRefPubMedPubMedCentral

Cuervo AM, Wong E (2014) Chaperone-mediated autophagy: roles in disease and aging. Cell Res 24(1):92–104. https://doi.org/10.1038/cr.2013.153 CrossRefPubMed

Tasset I, Cuervo AM (2016) Role of chaperone-mediated autophagy in metabolism. FEBS J 283(13):2403–2413. https://doi.org/10.1111/febs.13677 CrossRefPubMedPubMedCentral

Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M, Reggiori F (2018) Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. https://doi.org/10.1080/15548627.2018.1474314 CrossRefPubMedPubMedCentral

Hoekenga MT (1955) The treatment of malaria with hydrox source. Am J Trop Med Hyg 2:221–223CrossRef

Homewood CA, Warhurst DC, Peters W, Baggaley VC (1972) Lysosomes pH and anti malarial action of chlo source. Nature 235:5332–5350CrossRef

Nakagawa M, Sugawara K, Goto T, Wakui H, Nunomura W (2016) Hydroxychloroquine binding to cytoplasmic domain of Band 3 in human erythrocytes: Novel mechanistic insights into drug structure, efficacy and toxicity. Biochem Biophys Res Commun 473(4):999–1004. https://doi.org/10.1016/j.bbrc.2016.04.005 CrossRefPubMed

10.

Olsen NJ, Schleich MA, Karp DR (2013) Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum 43(2):264–272. https://doi.org/10.1016/j.semarthrit.2013.01.001 CrossRefPubMed

11.

Savarino A, Lucia MB, Giordano F, Cauda R (2006) Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol 7(10):792–793. https://doi.org/10.1016/s1470-2045(06)70875-0 CrossRefPubMed

12.

Sleightholm R, Yang B, Yu F, Xie Y, Oupický D (2017) Chloroquine-modified hydroxyethyl starch as a polymeric drug for cancer therapy. Biomacromolecules 18(8):2247–2257. https://doi.org/10.1021/acs.biomac.7b00023 CrossRefPubMedPubMedCentral

13.

Mizushima N, Komatsu M (2011) Autophagy: renovation of cells and tissues. Cell 147(4):728–741. https://doi.org/10.1016/j.cell.2011.10.026 CrossRefPubMed

14.

Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137(6):1062–1075. https://doi.org/10.1016/j.cell.2009.03.048 CrossRefPubMedPubMedCentral

15.

Lorente J, Velandia C, Leal JA, Garcia-Mayea Y, Lyakhovich A, Kondoh H, LLeonart ME (2017) The interplay between autophagy and tumorigenesis: exploiting autophagy as a means of anticancer therapy. Biol Rev Camb Philos Soc. https://doi.org/10.1111/brv.12337 CrossRefPubMed

16.

Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402(6762):672–676. https://doi.org/10.1038/45257 CrossRefPubMed

17.

Bae SY, Byun S, Bae SH, Min DS, Woo HA, Lee K (2017) TPT1 (tumor protein, translationally-controlled 1) negatively regulates autophagy through the BECN1 interactome and an MTORC1-mediated pathway. Autophagy 13(5):820–833. https://doi.org/10.1080/15548627.2017.1287650 CrossRefPubMedPubMedCentral

18.

Raina K, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R (2013) Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy 9(5):697–713. https://doi.org/10.4161/auto.23960 CrossRefPubMedPubMedCentral

19.

Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A (2017) Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Cancer Res 77(3):790–801. https://doi.org/10.1158/0008-5472.CAN-16-2400 CrossRefPubMed

20.

de la Rosa J, Weber J, Friedrich MJ, Li Y, Rad L, Ponstingl H, Liang Q, de Quiros SB, Noorani I, Metzakopian E, Strong A, Li MA, Astudillo A, Fernandez-Garcia MT, Fernandez-Garcia MS, Hoffman GJ, Fuente R, Vassiliou GS, Rad R, Lopez-Otin C, Bradley A, Cadinanos J (2017) A single-copy sleeping beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. Nat Genet 49(5):730–741. https://doi.org/10.1038/ng.3817 CrossRefPubMedPubMedCentral

21.

White E (2016) Autophagy and p53. Cold Spring Harbor perspectives in medicine 6 (4):a026120. https://doi.org/10.1101/cshperspect.a026120 CrossRefPubMedPubMedCentral

22.

Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Investig 112(12):1809–1820. https://doi.org/10.1172/JCI20039 CrossRefPubMedPubMedCentral

23.

Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci 100(25):15077–15082. https://doi.org/10.1073/pnas.2436255100 CrossRefPubMedPubMedCentral

24.

Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N (2011) Autophagy-deficient mice develop multiple liver tumors. Genes Dev 25(8):795–800. https://doi.org/10.1101/gad.2016211 CrossRefPubMedPubMedCentral

25.

Mandelbaum J, Rollins N, Shah P, Bowman D, Lee JY, Tayber O, Bernard H, LeRoy P, Li P, Koenig E, Brownell JE, D’Amore N (2015) Identification of a lung cancer cell line deficient in atg7-dependent autophagy. Autophagy. https://doi.org/10.1080/15548627.2015.1056966 CrossRefPubMed

26.

Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S, Duran A, Linares JF, Reina-Campos M, Umemura S, Valasek MA, Seki E, Yamaguchi K, Koike K, Itoh Y, Diaz-Meco MT, Moscat J, Karin M (2016) p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 29(6):935–948. https://doi.org/10.1016/j.ccell.2016.04.006 CrossRefPubMedPubMedCentral

27.

Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E (2007) Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 21(11):1367–1381. https://doi.org/10.1101/gad.1545107 CrossRefPubMedPubMedCentral

28.

Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10(1):51–64. https://doi.org/10.1016/j.ccr.2006.06.001 CrossRefPubMedPubMedCentral

29.

Wang Z, Cao L, Kang R, Yang M, Liu L, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Tang D (2014) Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy 7(4):401–411. https://doi.org/10.4161/auto.7.4.14397 CrossRef

30.

Shintani T (2004) Autophagy in health and disease: a double-edged sword. Science 306(5698):990–995. https://doi.org/10.1126/science.1099993 CrossRefPubMedPubMedCentral

31.

Marino G, Niso-Santano M, Baehrecke EH, Kroemer G (2014) Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 15(2):81–94. https://doi.org/10.1038/nrm3735 CrossRefPubMedPubMedCentral

32.

Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer cell 10(1):51–64. https://doi.org/10.1016/j.ccr.2006.06.001 CrossRefPubMedPubMedCentral

33.

Rebecca VW, Amaravadi RK (2016) Emerging strategies to effectively target autophagy in cancer. Oncogene 35(1):1–11. https://doi.org/10.1038/onc.2015.99 CrossRefPubMed

34.

White E (2015) The role for autophagy in cancer. J Clin Invest 125(1):42–46. https://doi.org/10.1172/JCI73941 CrossRefPubMedPubMedCentral

35.

Katheder NS, Khezri R, O’Farrell F, Schultz SW, Jain A, Rahman MM, Schink KO, Theodossiou TA, Johansen T, Juhasz G, Bilder D, Brech A, Stenmark H, Rusten TE (2017) Microenvironmental autophagy promotes tumour growth. Nature 541(7637):417–420. https://doi.org/10.1038/nature20815 CrossRefPubMedPubMedCentral

36.

Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, Anderson KI, Gottlieb E, Sansom OJ, Ryan KM (2013) p53 status determines the role of autophagy in pancreatic tumour development. Nature 504(7479):296–300. https://doi.org/10.1038/nature12865 CrossRefPubMed

37.

Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E (2013) Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 3(11):1272–1285. https://doi.org/10.1158/2159-8290.CD-13-0397 CrossRefPubMed

38.

Gammoh N, Fraser J, Puente C, Syred HM, Kang H, Ozawa T, Lam D, Acosta JC, Finch AJ, Holland E, Jiang X (2016) Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy 12(9):1431–1439. https://doi.org/10.1080/15548627.2016.1190053 CrossRefPubMedPubMedCentral

39.

Garcia-Prat L, Martinez-Vicente M, Perdiguero E, Ortet L, Rodriguez-Ubreva J, Rebollo E, Ruiz-Bonilla V, Gutarra S, Ballestar E, Serrano AL, Sandri M, Munoz-Canoves P (2016) Autophagy maintains stemness by preventing senescence. Nature 529(7584):37–42. https://doi.org/10.1038/nature16187 CrossRefPubMed

40.

Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell’antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev 25(7):717–729. https://doi.org/10.1101/gad.2016111 CrossRefPubMedPubMedCentral

41.

Guo JY, Xia B, White E (2013) Autophagy-mediated tumor promotion. Cell 155(6):1216–1219. https://doi.org/10.1016/j.cell.2013.11.019 CrossRefPubMedPubMedCentral

42.

Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, Von Hoff DD, Maitra A, Kimmelman AC (2014) Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 4(8):905–913. https://doi.org/10.1158/2159-8290.CD-14-0362 CrossRefPubMedPubMedCentral

43.

Kimmelman AC, White E (2017) Autophagy and tumor METABOLISM. Cell Metab 25(5):1037–1043. https://doi.org/10.1016/j.cmet.2017.04.004 CrossRefPubMedPubMedCentral

44.

Karvela M, Baquero P, Kuntz EM, Mukhopadhyay A, Mitchell R, Allan EK, Chan E, Kranc KR, Calabretta B, Salomoni P, Gottlieb E, Holyoake TL, Helgason GV (2016) ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy 12(6):936–948. https://doi.org/10.1080/15548627.2016.1162359 CrossRefPubMedPubMedCentral

45.

Barish S, Ochs MF, Sontag ED, Gevertz JL (2017) Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.1703355114 CrossRefPubMedPubMedCentral

46.

Zhao X, Subramanian S (2017) Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. Pharmacol Ther. https://doi.org/10.1016/j.pharmthera.2017.07.004 CrossRefPubMed

47.

Fowler DH (2014) Rapamycin-resistant effector T-cell therapy. Immunol Rev 257(1):210–225. https://doi.org/10.1111/imr.12127 CrossRefPubMedPubMedCentral

48.

Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062):1573–1557. https://doi.org/10.1126/science.1208347 CrossRefPubMed

49.

Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A, Falzoni S, Ryffel B, Apetoh L, Di Virgilio F, Madeo F, Maiuri MC, Zitvogel L, Levine B, Penninger JM, Kroemer G (2016) Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30(1):147–160. https://doi.org/10.1016/j.ccell.2016.05.016 CrossRefPubMedPubMedCentral

50.

Ratikan JA, Sayre JW, Schaue D (2013) Chloroquine engages the immune system to eradicate irradiated breast tumors in mice. Int J Radiat Oncol Biol Phys 87(4):761–768. https://doi.org/10.1016/j.ijrobp.2013.07.024 CrossRefPubMed

51.

Pasquier B (2016) Autophagy inhibitors. Cell Mol Life Sci 73(5):985–1001. https://doi.org/10.1007/s00018-015-2104-y CrossRefPubMed

52.

Pasquier B, El-Ahmad Y, Filoche-Romme B, Dureuil C, Fassy F, Abecassis PY, Mathieu M, Bertrand T, Benard T, Barriere C, El Batti S, Letallec JP, Sonnefraud V, Brollo M, Delbarre L, Loyau V, Pilorge F, Bertin L, Richepin P, Arigon J, Labrosse JR, Clement J, Durand F, Combet R, Perraut P, Leroy V, Gay F, Lefrancois D, Bretin F, Marquette JP, Michot N, Caron A, Castell C, Schio L, McCort G, Goulaouic H, Garcia-Echeverria C, Ronan B (2015) Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)- 3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. J Med Chem 58(1):376–400. https://doi.org/10.1021/jm5013352 CrossRefPubMed

53.

Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, Bachelot MF, Lamberton A, Mathieu M, Bertrand T, Marquette JP, El-Ahmad Y, Filoche-Romme B, Schio L, Garcia-Echeverria C, Goulaouic H, Pasquier B (2014) A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol 10(12):1013–1019. https://doi.org/10.1038/nchembio.1681 CrossRefPubMed

54.

Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, Menon S, Wang Z, Honda A, Pardee G, Cantwell J, Luu C, Cornella-Taracido I, Harrington E, Fekkes P, Lei H, Fang Q, Digan ME, Burdick D, Powers AF, Helliwell SB, D’Aquin S, Bastien J, Wang H, Wiederschain D, Kuerth J, Bergman P, Schwalb D, Thomas J, Ugwonali S, Harbinski F, Tallarico J, Wilson CJ, Myer VE, Porter JA, Bussiere DE, Finan PM, Labow MA, Mao X, Hamann LG, Manning BD, Valdez RA, Nicholson T, Schirle M, Knapp MS, Keaney EP, Murphy LO (2014) Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol 16(11):1069–1079. https://doi.org/10.1038/ncb3053 CrossRefPubMed

55.

Driessen S, Berleth N, Friesen O, Loffler AS, Bohler P, Hieke N, Stuhldreier F, Peter C, Schink KO, Schultz SW, Stenmark H, Holland P, Simonsen A, Wesselborg S, Stork B (2015) Deubiquitinase inhibition by WP1130 leads to ULK1 aggregation and blockade of autophagy. Autophagy 11(9):1458–1470. https://doi.org/10.1080/15548627.2015.1067359 CrossRefPubMedPubMedCentral

56.

Petherick KJ, Conway OJ, Mpamhanga C, Osborne SA, Kamal A, Saxty B, Ganley IG (2015) Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem 290(48):28726. https://doi.org/10.1074/jbc.A114.627778 CrossRefPubMedPubMedCentral

57.

Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, Lou HJ, Raveendra-Panickar D, Yang CC, Sheffler DJ, Teriete P, Asara JM, Turk BE, Cosford ND, Shaw RJ (2015) Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell 59(2):285–297. https://doi.org/10.1016/j.molcel.2015.05.031 CrossRefPubMedPubMedCentral

58.

Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, Joza N, Vitale I, Morselli E, Tailler M, Castedo M, Maiuri MC, Molgo J, Szabadkai G, Lavandero S, Kroemer G (2009) The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ 16(7):1006–1017. https://doi.org/10.1038/cdd.2009.34 CrossRefPubMed

59.

Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Norberg HV, Zhang T, Furuya T, Jin M, Zhu Z, Wang H, Yu J, Hao Y, Choi A, Ke H, Ma D, Yuan J (2011) Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147(1):223–234. https://doi.org/10.1016/j.cell.2011.08.037 CrossRefPubMedPubMedCentral

60.

Wang C, Hu Q, Shen HM (2016) Pharmacological inhibitors of autophagy as novel cancer therapeutic agents. Pharmacol Res 105:164–175. https://doi.org/10.1016/j.phrs.2016.01.028 CrossRefPubMed

61.

Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr (2010) Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980–4990. https://doi.org/10.1002/cncr.25426 CrossRefPubMed

62.

Lin CI, Whang EE, Lorch JH, Ruan DT (2012) Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery 152(6):1142–1149. https://doi.org/10.1016/j.surg.2012.08.016 CrossRefPubMed

63.

Nagelkerke A, Sieuwerts AM, Bussink J, Sweep FC, Look MP, Foekens JA, Martens JW, Span PN (2014) LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. Endocr Relat Cancer 21(1):101–112. https://doi.org/10.1530/ERC-13-0183 CrossRefPubMed

64.

Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP (2009) Autophagy: novel action of panitumumab in colon cancer. Anticancer Res 29(12):5077–5082PubMed

65.

Li X, Fan Z (2010) The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 70(14):5942–5952. https://doi.org/10.1158/0008-5472.CAN-10-0157 CrossRefPubMedPubMedCentral

66.

Tong Y, Liu YY, You LS, Qian WB (2012) Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin 33(4):542–550. https://doi.org/10.1038/aps.2011.192 CrossRefPubMedPubMedCentral

67.

Hamai A, Codogno P (2012) New targets for acetylation in autophagy. Sci Signal 5(231):pe29. https://doi.org/10.1126/scisignal.2003187 CrossRefPubMed

68.

Mukhopadhyay S, Sinha N, Das DN, Panda PK, Naik PP, Bhutia SK (2016) Clinical relevance of autophagic therapy in cancer: investigating the current trends, challenges, and future prospects. Crit Rev Clin Lab Sci 53(4):228–252. https://doi.org/10.3109/10408363.2015.1135103 CrossRefPubMed

69.

Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V, Cantore G, Giangaspero F, Fornai F (2013) Rapamycin inhibits the growth of glioblastoma. Brain Res 1495:37–51. https://doi.org/10.1016/j.brainres.2012.11.044 CrossRefPubMed

70.

Li H, Jin X, Zhang Z, Xing Y, Kong X (2013) Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Cell Biochem Funct 31(5):427–433. https://doi.org/10.1002/cbf.2917 CrossRefPubMed

71.

Yuan N, Song L, Lin W, Cao Y, Xu F, Liu S, Zhang A, Wang Z, Li X, Fang Y, Zhang H, Zhao W, Hu S, Wang J, Zhang S (2015) Autophagy collaborates with ubiquitination to downregulate oncoprotein E2A/Pbx1 in B-cell acute lymphoblastic leukemia. Blood Cancer J 5(1):e274–e274. https://doi.org/10.1038/bcj.2014.96 CrossRefPubMedPubMedCentral

72.

Liu R, Li J, Zhang T, Zou L, Chen Y, Wang K, Lei Y, Yuan K, Li Y, Lan J, Cheng L, Xie N, Xiang R, Nice EC, Huang C, Wei Y (2014) Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking. Autophagy 10(7):1241–1255. https://doi.org/10.4161/auto.28912 CrossRefPubMedPubMedCentral

73.

Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS (2014) Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 59(2):505–517. https://doi.org/10.1002/hep.26659 CrossRefPubMed

74.

Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS (2014) Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis. Autophagy 10(9):1687–1689. https://doi.org/10.4161/auto.29959 CrossRefPubMedPubMedCentral

75.

Yuk JM, Shin DM, Song KS, Lim K, Kim KH, Lee SH, Kim JM, Lee JS, Paik TH, Kim JS, Jo EK (2010) Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy 6(1):46–60CrossRefPubMed

76.

Chang CT, Hseu YC, Thiyagarajan V, Lin KY, Way TD, Korivi M, Liao JW, Yang HL (2017) Chalcone flavokawain B induces autophagic-cell death via reactive oxygen species-mediated signaling pathways in human gastric carcinoma and suppresses tumor growth in nude mice. Arch Toxicol. https://doi.org/10.1007/s00204-017-1967-0 CrossRefPubMed

77.

Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, He G, Yang S, Ouyang L, Liu B (2017) Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. Chem Sci 8(4):2687–2701. https://doi.org/10.1039/c6sc05368h CrossRefPubMedPubMedCentral

78.

Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, Woo J, Gyorffy B, Gabrielson E, Saxena NK, Sharma D (2017) ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis. Autophagy:1–18. https://doi.org/10.1080/15548627.2017.1332565 CrossRefPubMedPubMedCentral

79.

Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK (2015) Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21(2):448–459. https://doi.org/10.1158/1078-0432.CCR-14-1578 CrossRefPubMed

80.

Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M, Trisciuoglio D (2014) Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer 13:230. https://doi.org/10.1186/1476-4598-13-230 CrossRefPubMedPubMedCentral

81.

Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, Lu B (2008) Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 4(5):659–668CrossRefPubMed

82.

Beljanski V, Knaak C, Smith CD (2010) A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 333(2):454–464. https://doi.org/10.1124/jpet.109.163337 CrossRefPubMedPubMedCentral

83.

Li HY, Zhang J, Sun LL, Li BH, Gao HL, Xie T, Zhang N, Ye ZM (2015) Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study. Cell Death Dis 6:e1604. https://doi.org/10.1038/cddis.2014.543 CrossRefPubMedPubMedCentral

84.

Hong EH, Heo EY, Song JH, Kwon BE, Lee JY, Park Y, Kim J, Chang SY, Chin YW, Jeon SM, Ko HJ (2017) Trans-scirpusin A showed antitumor effects via autophagy activation and apoptosis induction of colorectal cancer cells. Oncotarget 8(25):41401–41411. https://doi.org/10.18632/oncotarget.17388 CrossRefPubMedPubMedCentral

85.

Bommareddy A, Hahm ER, Xiao D, Powolny AA, Fisher AL, Jiang Y, Singh SV (2009) Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 69(8):3704–3712. https://doi.org/10.1158/0008-5472.CAN-08-4344 CrossRefPubMedPubMedCentral

86.

Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG (2012) Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 109(43):17537–17542. https://doi.org/10.1073/pnas.1202870109 CrossRefPubMedPubMedCentral

87.

Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H (2013) Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104(1):22–27. https://doi.org/10.1111/cas.12075 CrossRefPubMedPubMedCentral

88.

Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J, Kumar V, van de Vosse E, Wijmenga C, van Crevel R, Oosterwijk E, Grotenhuis AJ, Vermeulen SH, Kiemeney LA, van de Veerdonk FL, Chamilos G, Xavier RJ, van der Meer JW, Netea MG, Joosten LA (2014) Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog 10(10):e1004485. https://doi.org/10.1371/journal.ppat.1004485 CrossRefPubMedPubMedCentral

89.

Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM, Saluja AK (2007) Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 67(19):9407–9416. https://doi.org/10.1158/0008-5472.CAN-07-1077 CrossRefPubMed

90.

Mujumdar N, Mackenzie TN, Dudeja V, Chugh R, Antonoff MB, Borja-Cacho D, Sangwan V, Dawra R, Vickers SM, Saluja AK (2010) Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology 139(2):598–608. https://doi.org/10.1053/j.gastro.2010.04.046 CrossRefPubMed

91.

Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, Li ZM (2010) Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy 6(6):777–783CrossRefPubMed

92.

Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, Chen SJ, Zhao WL (2013) Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol 6:53. https://doi.org/10.1186/1756-8722-6-53 CrossRefPubMedPubMedCentral

93.

De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12(6):594–603. https://doi.org/10.1016/S1470-2045(10)70209-6 CrossRefPubMed

94.

Goulielmaki M, Koustas E, Moysidou E, Vlassi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, Pintzas A (2016) BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. Oncotarget 7(8):9188–9221. https://doi.org/10.18632/oncotarget.6942 CrossRefPubMedPubMedCentral

95.

Wiersma VR, de Bruyn M, Wei Y, van Ginkel RJ, Hirashima M, Niki T, Nishi N, Zhou J, Pouwels SD, Samplonius DF, Nijman HW, Eggleton P, Helfrich W, Bremer E (2015) The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy 11(8):1373–1388. https://doi.org/10.1080/15548627.2015.1063767 CrossRefPubMedPubMedCentral

96.

Yang A, Kimmelman AC (2014) Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 status. Autophagy 10(9):1683–1684. https://doi.org/10.4161/auto.29961 CrossRefPubMedPubMedCentral

97.

Yao W, Yue P, Zhang G, Owonikoko TK, Khuri FR, Sun SY (2015) Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett 364(1):70–78. https://doi.org/10.1016/j.canlet.2015.04.028 CrossRefPubMedPubMedCentral

98.

Vyas AR, Hahm ER, Arlotti JA, Watkins S, Stolz DB, Desai D, Amin S, Singh SV (2013) Chemoprevention of prostate cancer by d,l-sulforaphane is augmented by pharmacological inhibition of autophagy. Cancer Res 73(19):5985–5995. https://doi.org/10.1158/0008-5472.CAN-13-0755 CrossRefPubMedPubMedCentral

99.

Zanotto-Filho A, Braganhol E, Klafke K, Figueiro F, Terra SR, Paludo FJ, Morrone M, Bristot IJ, Battastini AM, Forcelini CM, Bishop AJ, Gelain DP, Moreira JC (2015) Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Lett 358(2):220–231. https://doi.org/10.1016/j.canlet.2014.12.044 CrossRefPubMed

100.

Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K (2017) CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun 8:15916. https://doi.org/10.1038/ncomms15916 CrossRefPubMedPubMedCentral

101.

Wu Y, Ni Z, Yan X, Dai X, Hu C, Zheng Y, He F, Lian J (2016) Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin. Autophagy 12(7):1105–1117. https://doi.org/10.1080/15548627.2016.1173798 CrossRefPubMedPubMedCentral

102.

Chang CM, Lan KL, Huang WS, Lee YJ, Lee TW, Chang CH, Chuang CM (2017) 188Re-liposome can induce mitochondrial autophagy and reverse drug resistance for ovarian cancer: from bench evidence to preliminary clinical proof-of-concept. Int J Mol Sci. https://doi.org/10.3390/ijms18050903 CrossRefPubMedPubMedCentral

103.

Eritja N, Chen BJ, Rodriguez-Barrueco R, Santacana M, Gatius S, Vidal A, Marti MD, Ponce J, Bergada L, Yeramian A, Encinas M, Ribera J, Reventos J, Boyd J, Villanueva A, Matias-Guiu X, Dolcet X, Llobet-Navas D (2017) Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 13(3):608–624. https://doi.org/10.1080/15548627.2016.1271512 CrossRefPubMedPubMedCentral

104.

Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang CY, Zen K, Li L (2017) MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 8(1):e2540. https://doi.org/10.1038/cddis.2016.461 CrossRefPubMedPubMedCentral

105.

Wang K, Liu R, Li J, Mao J, Lei Y, Wu J, Zeng J, Zhang T, Wu H, Chen L, Huang C, Wei Y (2011) Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1alpha-mediated signaling. Autophagy 7(9):966–978CrossRefPubMed

106.

Giuliano S, Cormerais Y, Dufies M, Grepin R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S, Mazure NM, Benhida R, Auberger P, Mograbi B, Pages G (2015) Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. Autophagy 11(10):1891–1904. https://doi.org/10.1080/15548627.2015.1085742 CrossRefPubMedPubMedCentral

107.

Wang Z, Liu Z, Wu S (2017) Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget 8(19):31465–31477. https://doi.org/10.18632/oncotarget.16356 CrossRefPubMedPubMedCentral

108.

Li J, Yang D, Wang W, Piao S, Zhou J, Saiyin W, Zheng C, Sun H, Li Y (2015) Inhibition of autophagy by 3-MA enhances IL-24-induced apoptosis in human oral squamous cell carcinoma cells. J Exp Clin Cancer Res 34:97. https://doi.org/10.1186/s13046-015-0211-0 CrossRefPubMedPubMedCentral

109.

Sheen JH, Zoncu R, Kim D, Sabatini DM (2011) Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19(5):613–628. https://doi.org/10.1016/j.ccr.2011.03.012 CrossRefPubMedPubMedCentral

110.

Herranz D, Ambesi-Impiombato A, Sudderth J, Sanchez-Martin M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, Marquez J, Mates JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA (2015) Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med 21(10):1182–1189. https://doi.org/10.1038/nm.3955 CrossRefPubMedPubMedCentral

111.

Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, Chouaib S (2011) Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 71(18):5976–5986. https://doi.org/10.1158/0008-5472.CAN-11-1094 CrossRefPubMed

112.

Akin D, Wang SK, Habibzadegah-Tari P, Law B, Ostrov D, Li M, Yin XM, Kim JS, Horenstein N, Dunn WA Jr (2014) A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy 10(11):2021–2035. https://doi.org/10.4161/auto.32229 CrossRefPubMedPubMedCentral

113.

Whelan KA, Chandramouleeswaran PM, Tanaka K, Natsuizaka M, Guha M, Srinivasan S, Darling DS, Kita Y, Natsugoe S, Winkler JD, Klein-Szanto AJ, Amaravadi RK, Avadhani NG, Rustgi AK, Nakagawa H (2017) Autophagy supports generation of cells with high CD44 expression via modulation of oxidative stress and Parkin-mediated mitochondrial clearance. Oncogene. https://doi.org/10.1038/onc.2017.102 CrossRefPubMedPubMedCentral

114.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchiano A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM (2012) Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol 158(1):108–119. https://doi.org/10.1111/j.1365-2141.2012.09139.x CrossRefPubMed

115.

Holmes FA, Espina V, Liotta LA, Nagarwala YM, Danso M, McIntyre KJ, Osborne CR, Anderson T, Krekow L, Blum JL, Pippen J, Florance A, Mahoney J, O’Shaughnessy JA (2013) Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res Notes 6:507. https://doi.org/10.1186/1756-0500-6-507 CrossRefPubMedPubMedCentral

116.

Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5(9):726–734. https://doi.org/10.1038/nrc1692 CrossRefPubMed

117.

Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, Schrag D, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC (2014) Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 19(6):637–638. https://doi.org/10.1634/theoncologist.2014-0086 CrossRefPubMedPubMedCentral

118.

Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS (2014) Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10(8):1403–1414. https://doi.org/10.4161/auto.29231 CrossRefPubMedPubMedCentral

119.

Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK (2014) Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10(8):1380–1390. https://doi.org/10.4161/auto.29264 CrossRefPubMedPubMedCentral

120.

Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O’Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK (2014) Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10(8):1369–1379. https://doi.org/10.4161/auto.29118 CrossRefPubMedPubMedCentral

121.

Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, Tan KS, Heitjan DF, DeMichele AM, Vaughn DJ, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O’Dwyer PJ, Amaravadi RK (2014) Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10(8):1391–1402. https://doi.org/10.4161/auto.29119 CrossRefPubMedPubMedCentral

122.

Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A, Ortega-Gomez A, Gamboa-Vignolle C, Nunez-Gomez R, Dorantes-Gallareta Y, Arce-Salinas C, Arrieta O (2013) Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol 8:209. https://doi.org/10.1186/1748-717X-8-209 CrossRefPubMedPubMedCentral

123.

Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, Tan KS, Pontiggia L, O’Dwyer PJ, Davis LE, Amaravadi RK (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10(8):1359–1368. https://doi.org/10.4161/auto.28984 CrossRefPubMedPubMedCentral

124.

Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Zeh HJ (2015) Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol 22(13):4402–4410. https://doi.org/10.1245/s10434-015-4566-4 CrossRefPubMedPubMedCentral

125.

Vega-Rubín-de-Celis S, Zou Z, Fernández ÁF, Ci B, Kim M, Xiao G, Xie Y, Levine B (2018) Increased autophagy blocks HER2-mediated breast tumorigenesis. Proc Natl Acad Sci 115(16):4176–4181. https://doi.org/10.1073/pnas.1717800115 CrossRefPubMedPubMedCentral

Titel: Autophagy therapeutics: preclinical basis and initial clinical studies
verfasst von: Lei Zhan
Jun Li
Bing Wei
Publikationsdatum: 17.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3688-3

Springer Medizin

Autophagy therapeutics: preclinical basis and initial clinical studies

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Autophagy modulation: a prudent approach in cancer treatment?

Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer

Acknowledgements of reviewers 2017

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie